Please visit answersincme.com/CFN860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, two experts in oncology discuss current and emerging treatments for unresectable stage I to III EGFR mutation–positive non–small-cell lung cancer. Upon completion of this activity, participants should be better able to: Review best practices for integrating biomarker testing into practice for stage I to III NSCLC; Describe the clinical profiles of current and emerging therapeutic approaches for the management of stage I to III NSCLC; and Outline multidisciplinary strategies to optimize the integration of a targeted approach into clinical practice for patients with stage I to III NSCLC.
View all episodes
